
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure is a promising oncology company with a strong and diverse pipeline, highlighted by its proprietary TTFields technology. The company's recent record revenue quarter and upwardly revised 2026 revenue and expense guidance demonstrate strong execution on the commercial side. The full launch of Optune Pax and the potential for M&A or broader de-risking of TTFields offer upside potential to the company's already successful GBM franchise.
Bears say
NovoCure is facing competition in the lung market, limited treatment duration, and high operating expenses as indicated by their 2Q26 results and 2026 financial estimates, leading to a negative outlook on their stock. Additionally, their growth is heavily reliant on expanding beyond their core GBM franchise and further adoption of their newer products, which may not result in substantial growth.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares